TAPI 0
Biological Activity
ADAM-17 (TACE) and MMP inhibitor; attenuates TNF-α processing. Acts in concert with GM6001 (Cat. No. 2983) to inhibit Chlamydia trachomatis growth.
Technical Data
| M. Wt | 456.54 |
| Formula | C24H32N4O5 |
| Storage | Store at -20°C |
| Purity | ≥95% (HPLC) |
| CAS Number | 163958-73-4 |
| PubChem ID | 3035404 |
| InChI Key | CRCPLBFLOSEABN-VBSNWNEZSA-N |
| Smiles | ONC(C[C@@H](CC(C)C)C(N[C@@H](CC1=CC(C=CC=C2)=C2C=C1)C(N[C@@H](C)C(N)=O)=O)=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solubility | Soluble to 10 mg/ml in DMSO |
Preparing Stock Solutions
The following data is based on the product molecular weight 456.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.19 mL | 10.95 mL | 21.9 mL |
| 5 mM | 0.44 mL | 2.19 mL | 4.38 mL |
| 10 mM | 0.22 mL | 1.1 mL | 2.19 mL |
| 50 mM | 0.04 mL | 0.22 mL | 0.44 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Balakrishnan et al (2006) Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J.Biol.Chem. 281 16691 PMID: 16565079
Rzeniewicz et al (2015) L-selectin shedding is activated specifically within transmigrating pseudopods of monocytes to regulate cell polarity in vitro. Proc.Natl.Acad.Sci.USA. 112 E1461 PMID: 25775539
If you know of a relevant reference for TAPI 0, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TAPI 0, supplier, TAPI0, ADAM17, metalloproteases, MMPs, metalloproteinases, inhibits, inhibitors, adams, TNFa, TNFα, converting, enzyme, TACE, TNF-a, processing, inhibitor-0, TNF-a, processing, inhibitor-0, ADAMs, Matrix, Metalloprotease, ADAMs, Tocris Bioscience
Citations for TAPI 0
Citations are publications that use Tocris products.
Currently there are no citations for TAPI 0. Do you know of a great paper that uses TAPI 0 from Tocris? If so please let us know.
Reviews for TAPI 0
There are currently no reviews for this product. Be the first to review TAPI 0 and earn rewards!
Have you used TAPI 0?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and Europe
Submit a ReviewLiterature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Immunology Product Listing
A collection of over 190 products for immunology research, the guide includes research tools for the study of:
- Chemokine and Cytokine Signaling
- Chemotaxis
- Complement System
- Immune Cell Signaling
- Inflammation
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
